[
  {
    "ts": null,
    "headline": "Quest Diagnostics (DGX): Assessing Valuation Following Launch of Nationwide Pharmacogenomic Test for Precision Medicine",
    "summary": "Quest Diagnostics (DGX) recently caught the market’s eye with the launch of an advanced pharmacogenomic laboratory test. The new test aims to help healthcare providers personalize drug therapies based on a patient’s genetic profile. Supported by Coriell Life Sciences technology, this service is positioned as a game changer for clinicians across a wide range of specialties. It offers actionable guidance that could make prescribing both safer and more effective. This launch also signals a...",
    "url": "https://finnhub.io/api/news?id=a8fd2744b8486331f0afaf258ef12bb69fcea1df3b79c6a3e4552e7ea16a532b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757344469,
      "headline": "Quest Diagnostics (DGX): Assessing Valuation Following Launch of Nationwide Pharmacogenomic Test for Precision Medicine",
      "id": 136690815,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DGX",
      "source": "Yahoo",
      "summary": "Quest Diagnostics (DGX) recently caught the market’s eye with the launch of an advanced pharmacogenomic laboratory test. The new test aims to help healthcare providers personalize drug therapies based on a patient’s genetic profile. Supported by Coriell Life Sciences technology, this service is positioned as a game changer for clinicians across a wide range of specialties. It offers actionable guidance that could make prescribing both safer and more effective. This launch also signals a...",
      "url": "https://finnhub.io/api/news?id=a8fd2744b8486331f0afaf258ef12bb69fcea1df3b79c6a3e4552e7ea16a532b"
    }
  },
  {
    "ts": null,
    "headline": "3 Reasons to Sell DGX and 1 Stock to Buy Instead",
    "summary": "Even though Quest (currently trading at $183.49 per share) has gained 6% over the last six months, it has lagged the S&P 500’s 15.5% return during that period. This might have investors contemplating their next move.",
    "url": "https://finnhub.io/api/news?id=8e0cc1eb7aa66e3068cba78abf6a486d38e8cde9d5395b255e764dfb2c921075",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757307865,
      "headline": "3 Reasons to Sell DGX and 1 Stock to Buy Instead",
      "id": 136669736,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DGX",
      "source": "Yahoo",
      "summary": "Even though Quest (currently trading at $183.49 per share) has gained 6% over the last six months, it has lagged the S&P 500’s 15.5% return during that period. This might have investors contemplating their next move.",
      "url": "https://finnhub.io/api/news?id=8e0cc1eb7aa66e3068cba78abf6a486d38e8cde9d5395b255e764dfb2c921075"
    }
  }
]